

Thomas Jefferson University Jefferson Digital Commons

Phase 1 Class of 2023

2-2021

Risk Factors and Effect of Acute Kidney Injury on Outcomes Following Total Hip and Knee Arthroplasty

Zachary S. Aman

Michael Yayac

Alexander J. Rondon

Timothy L. Tan

P. Maxwell Courtney

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2023_phase1

Part of the Translational Medical Research Commons

Let us know how access to this document benefits you

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson Scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@iefferson.edu.

Authors Zachary S. Aman, Purtill	, Michael Yayac, Alexande	r J. Rondon, Timothy L. Tan,	P. Maxwell Courtney, and James J.



Risk Factors and Effect of Acute Kidney Injury on Outcomes Following Total Hip and Knee Arthroplasty

Zachary S. Aman, BA, Michael Yayac, MD, Alexander J. Rondon, MD, Timothy L. Tan, MD, P. Maxwell Courtney, MD, James J. Purtill, MD*



J Arthroplasty. 2020 Aug 1;S0883-5403(20)30865-2. doi: 10.1016/j.arth.2020.07.072.
Online ahead of print.

Risk Factors and Effect of Acute Kidney Injury on Outcomes Following Total Hip and Knee Arthroplasty

Michael Yayac ¹, Zachary S Aman ², Alexander J Rondon ³, Timothy L Tan ³, P Maxwell Courtney ¹, James J Purtill ¹

Affiliations + expand

PMID: 32839060 DOI: 10.1016/j.arth.2020.07.072



Introduction

Acute Kidney Injury

- Abrupt decrease in kidney function due to structural or functional damage¹:
 - Several etiologies: ischemia, nephrotoxicity, obstruction, etc.
 - Known to significantly complicate clinical course and worsen outcomes in hospitalized patients

AKI After TJA

- 2- 15% of THA and TKA patients²
- Potentially avoidable complication related to negative outcomes
- longer LOS, increased readmission rates, and increased healthcare costs³
- Can lead to CKD²

Risk Factors for AKI

- Increased age, CHF, postoperative hypotension, and hepatic failure⁴⁻⁶
- In post-cardiac surgery patients, anemia has been reported to be a risk factor for AKI⁷⁻¹⁰ → medullary hypoxia¹¹
- Gharaibeh et al reported that for every 5-kg/m2 increase in BMI, patients had a 40% increase risk of AKI post-THA¹²



Introduction

- There remains limited information regarding the association of modifiable risk factors and AKI post-TJA
 - Anemia, length of surgery, blood loss, antibiotics, etc.
- How can surgeons better identify and proactively mitigate modifiable risk factors of AKI?
 - Risk reduction can lead to improved outcomes and lower costs



Purpose & Hypothesis

Purpose:

- 1)To determine the effect of AKI on short-term outcomes
- 2) to identify risk factors for developing AKI following THA and TKA


Hypothesis:

- 1) AKI has significant adverse effects on shortterm outcomes metrics including length of stay, discharge, and complications
- 1 Increased BMI and inadequate intraoperative renal perfusion are modifiable risk factors associated with postoperative AKI



Methods: Overview

- Study design: Retrospective Case Control
- Data source and collection: Rothman Orthopedic Institute Database
- Population/study sample: Patients undergoing THA or TKA between 2005 and 2017 with minimum 2-year f/u
- Intervention: THA or TKA
- Comparison group: Patients who developed AKI vs. Patients who did not post-op
- Outcome: 1) Risk factors for the development of AKI and 2) AKI effect on post-operative pt. outcomes vs. controls





Medical College Methods: Data Collection at Thomas Jefferson University

Data Collection

- Demographics
- Operative Variables
 - Surgical time, antibiotic prophylaxis, EBL, Hgb
- Medical comorbidities
 - CHF, dementia, CKD, DM, etc.
- Outcomes Measures
 - Complications, LOS, discharge to facility, readmission, 90-day mortality
- Creatinine level measurement (pre/post)
 - AKI defined as increased in serum creatinine by 50% or 0.3mg/dl on postop day 1 from preop measurements



Methods: Analysis

Statistical analyses

- performed to identify significant risk factors in patients who developed AKI and its effect on postoperative outcomes as compared to control
 - Continuous variables → Mann-Whitney test
 - Categorical variables → Chi-square analysis



Results: Risk Factors

Demographics

- 20,800 patients who underwent unilateral primary THA (n=10,601) or TKA (n=10,199) from 2005 to 2017
- 814 (3.9%) patients developed AKI vs. 19, 986 patients did not develop AKI

Patient Risk Factors

- Patients who developed AKI had significantly higher:
 - Age (66.4 vs 63.4, p<0.001)
 - BMI (31.8 vs 30.0, p<0.001)
 - Rates of 10 of the 17 assessed comorbidities (Appendix 1)

Operative Risk Factors

- Patients who developed AKI had:
 - Significantly lower Preoperative Hgb levels (13.1 vs. 13.5, p<0.001).
 - more likely to undergo TKA (55% vs 49%, p=0.002)
 - Significantly longer operative times (90 vs. 79 min, p<0.001),
 - less likely to receive TXA (14% vs. 22%, p<0.001),
 - Received greater intraoperative RBC transfusion units (2.1 vs 0.4, p=0.015)



Results: Outcomes

Clinical Outcomes

- Patients developing AKI had significantly higher:
 - rates of all in-hospital complication types except for gastrointestinal complications
 - greater LOS (3.6 vs 2.8 days, p<0.001)</p>
 - discharge to facility rates (37% vs 23%, p<0.001)
 - 90-day mortality rates (1% vs. 0.1%, p<0.001)
 - 1-year PJI rates (1.8% vs. 0.7%, p=0.001)

Multivariate Analysis

- AKI significantly increased
 - LOS by 0.26 days (95% CI 0.14-0.38, p<0.001).
 - Risk of in-hospital complications (OR=1.73, 95% CI 1.45-2.07,p<0.001)
 - Risk of being discharged to a facility (OR=1.26, 95% CI 1.05-1.53, p=0.012)



Conclusions

- AKI has significant adverse effects on shortterm outcomes metrics including length of stay, discharge to a facility, and increased rate of in-hospital complications
- While most risk factors for developing AKI may not be modifiable, efforts to reduce BMI preoperatively and maintaining adequate renal perfusion (anemia, estimated blood loss, and length of surgery) intraoperatively may aid in mitigating this risk.



Future Directions

- Future studies should be performed to determine if employing strategies to address modifiable risk factors pre- and intraoperatively reduce the incidence of AKI in patients undergoing TJA
- Treatment of anemia prior to TJA may be beneficial to prevent AKI
- Efforts to limit blood loss, such as using TXA, which demonstrated a protective effect in our analysis, may be effective in reducing risk of AKI



References

- [1] Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012; 2: 1-138. n.d.
- [2] Rudy MD, Ahuja NK. Acute Kidney Injury in Lower-Extremity Joint Arthroplasty: Clinical Epidemiology, Prevention, and Management. JBJS Reviews 2019;7:e9. https://doi.org/10.2106/JBJS.RVW.18.00121.
- [3] Abar O, Toossi N, Johanson N. Cost and determinants of acute kidney injury after elective primary total joint arthroplasty. Arthroplast Today 2018;4:335-9. https://doi.org/10.1016/j.artd.2018.05.002.
- [4] Lands VW, Malige A, Carmona A, Roscher CR, Gayner RS, Rowbotham J, et al. Reducing Hypotension and Acute Kidney Injury in the Elective Total Joint Arthroplasty Population: A Multi-Disciplinary Approach. The Journal of Arthroplasty 2018;33:1686-92. https://doi.org/10.1016/j.arth.2018.01.061.
- [5] Weingarten TN, Gurrieri C, Jarett PD, Brown DR, Berntson NJ, Calaro RD, et al. Acute kidney injury following total joint arthroplasty: retrospective analysis. Can J Anaesth 2012;59:1111-8. https://doi.org/10.1007/s12630-012-9797-2.
- [6] Warth LC, Noiseux NO, Hogue MH, Klaassen AL, Liu SS, Callaghan JJ. Risk of Acute Kidney Injury After Primary and Revision Total Hip Arthroplasty and Total Knee Arthroplasty Using a Multimodal Approach to Perioperative Pain Control Including Ketorolac and Celecoxib. J Arthroplasty 2016;31:253-5. https://doi.org/10.1016/j.arth.2015.08.012.
- [7] Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wong P-Y, et al. Influence of erythrocyte transfusion on the risk of acute kidney injury after cardiac surgery differs in anemic and nonanemic patients. Anesthesiology 2011;115:523-30. https://doi.org/10.1097/ALN.0b013e318229a7e8.
- [8] Karkouti K, Grocott HP, Hall R, Jessen ME, Kruger C, Lerner AB, et al. Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: a historical multicentre cohort study. Can J Anaesth 2015;62:377-84. https://doi.org/10.1007/s12630-014-0302-y.
- [9] Walsh M, Garg AX, Devereaux PJ, Argalious M, Honar H, Sessler DI. The association between perioperative hemoglobin and acute kidney injury in patients having noncardiac surgery. Anesth Analg 2013;117:924-31. https://doi.org/10.1213/ANE.0b013e3182a1ec84.
- [10] Rosenberger C, Rosen S, Heyman SN. Renal parenchymal oxygenation and hypoxia adaptation in acute kidney injury. Clin Exp Pharmacol Physiol 2006;33:980-8. https://doi.org/10.1111/j.1440-1681.2006.04472.x.
- [11] Park JT. Postoperative acute kidney injury. Korean J Anesthesiol 2017;70:258-66. https://doi.org/10.4097/kjae.2017.70.3.258.
- **[12]** Gharaibeh KA, Hamadah AM, Sierra RJ, Leung N, Kremers WK, El-Zoghby ZM. The Rate of Acute Kidney Injury After Total Hip Arthroplasty Is Low but Increases Significantly in Patients with Specific Comorbidities: The Journal of Bone and Joint Surgery 2017;99:1819-26. https://doi.org/10.2106/JBJS.16.01027.



Appendix 1.
Patient
Demographics
and
Comorbidities
by groups of
`AKI'

	No N=19986	Yes <i>N=814</i>	p-value
Patient Age	63.4 (11.3)	66.4 (11.1)	<0.001
Body Mass Index	30.0 (5.73)	31.8 (6.20)	<0.001
Sex			<0.001
Female	11171 (55.9%)	367 (45.1%)	
Male	8815 (44.1%)	447 (54.9%)	
Medical Comorbidities			
Anemia	6777 (34.1%)	433 (53.4%)	<0.001
AIDS	17 (0.09%)	3 (0.37%)	0.041
Congestive Heart Failure	336 (1.68%)	50 (6.14%)	<0.001
Chronic Pulmonary Disease	2392 (12.0%)	125 (15.4%)	0.004
Cerebrovascular Disease	230 (1.15%)	20 (2.46%)	0.001
Dementia	27 (0.14%)	5 (0.61%)	0.008
Diabetes Mellitus	252 (1.26%)	22 (2.70%)	0.001
Hemiparesis	6 (0.03%)	1 (0.12%)	0.244
Malignancy	218 (1.09%)	14 (1.72%)	0.132
Metastatic Disease	45 (0.23%)	3 (0.37%)	0.437
Myocardial Infarction	844 (4.22%)	67 (8.23%)	<0.001
Mild Liver Disease	90 (0.45%)	6 (0.74%)	0.280
Moderate-Severe Liver Disease	12 (0.06%)	2 (0.25%)	0.102
Peptic Ulcer Disease	73 (0.37%)	5 (0.61%)	0.234
Peripheral Vascular Disease	261 (1.31%)	24 (2.95%)	< 0.001
Chronic Kidney Disease	315 (1.58%)	74 (9.09%)	<0.001
Connective Tissue Disease	650 (3.25%)	32 (3.93%)	0.334
Charlson Comorbidity Index	0.40 (0.88)	0.84 (1.43)	<0.001



Appendix 1 (continued). Patient Demographics and Comorbidities by groups of `AKI'

No	Vac	p-value
N=19986	N=814	p-varae
		<0.001
1830 (9.16%)	52 (6.39%)	0.007
6821 (34.1%)	333 (40.9%)	<0.001
11334 (56.7%)	429 (52.7%)	0.024
		0.203
19557 (97.9%)	798 (98.0%)	
250 (1.25%)	13 (1.60%)	
178 (0.89%)	3 (0.37%)	
0.90 (0.30)	1.11 (1.11)	< 0.001
17.7 (6.30)	20.2 (8.05)	< 0.001
13.5 (1.41)	13.1 (1.62)	< 0.001
	1830 (9.16%) 6821 (34.1%) 11334 (56.7%) 19557 (97.9%) 250 (1.25%) 178 (0.89%) 0.90 (0.30) 17.7 (6.30)	N=19986 N=814 1830 (9.16%) 52 (6.39%) 6821 (34.1%) 333 (40.9%) 11334 (56.7%) 429 (52.7%) 19557 (97.9%) 798 (98.0%) 250 (1.25%) 13 (1.60%) 178 (0.89%) 3 (0.37%) 0.90 (0.30) 1.11 (1.11) 17.7 (6.30) 20.2 (8.05)



Appendix 2. Outcomes by groups of `AKI'

	No <i>N=19986</i>	Yes <i>N=814</i>	p-value
Postoperative Creatinine	0.87 (0.27)	1.59 (1.28)	0.000
Postoperative BUN	13.2 (5.62)	23.3 (9.32)	<0.001
Postoperative Hemoglobin	10.4 (1.43)	9.82 (1.49)	<0.001
Complication	3416 (17.1%)	267 (33.0%)	< 0.001
Cardiovascular Complications	656 (3.28%)	45 (5.53%)	0.001
DVT/PE	152 (0.76%)	15 (1.84%)	0.001
Pulmonary Complications	148 (0.74%)	18 (2.21%)	<0.001
GI Complications	1153 (5.77%)	41 (5.04%)	0.422
GU Complications	300 (1.50%)	90 (11.1%)	< 0.001
Neurological Complications	182 (0.91%)	17 (2.09%)	0.001
Infectious Complications	210 (1.05%)	17 (2.09%)	0.009
Discharge to Facility	4666 (23.4%)	301 (37.4%)	< 0.001
Length of Stay	2.76 (2.37)	3.59 (2.59)	< 0.001
Readmission	793 (3.97%)	42 (5.16%)	0.108
90-day Mortality	28 (0.14%)	8 (0.98%)	< 0.001
1-year PJI	143 (0.72%)	15 (1.84%)	0.001



Appendix 3.
Relative
Variable
Importance

